Moreover, several case reports and clinical studies indicate that alpelisib is well tolerated and demonstrates activity in patients with advanced gynecologic cancers harboring activating mutations in PIK3CA (NCT01219699, NCT04085653). The gene discussed is PIK3CA; the disease is female reproductive organ cancer.